Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Time to Buy?

Key Points

• Pharvaris N.V. (NASDAQ:PHVS) experienced a significant volume increase, with 151,791 shares traded, marking a 110% rise compared to the previous session.
• The company has an average analyst rating of "Buy", with target prices ranging from $25.00 to $36.20, according to several recent research reports.
• Pharvaris reported earnings of ($0.89) per share, missing expectations, while analysts forecast a -2.71 EPS for the current year.
• Institutional investors, including FMR LLC and Soleus Capital Management, have recently increased their stakes in Pharvaris, indicating growing investor interest.

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 151,791 shares traded hands during trading, an increase of 110% from the previous session's volume of 72,289 shares.The stock last traded at $20.02 and had previously closed at $20.05.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PHVS shares. Guggenheim started coverage on Pharvaris in a research report on Wednesday, June 11th. They set a "buy" rating and a $32.00 price target on the stock. Wedbush restated an "outperform" rating and set a $27.00 price target on shares of Pharvaris in a research report on Thursday, June 5th. Finally, Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $36.20.

Pharvaris Trading Down 2.0%

The company has a 50-day simple moving average of $18.47 and a two-hundred day simple moving average of $16.95.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). On average, equities research analysts anticipate that Pharvaris N.V. will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in shares of Pharvaris during the fourth quarter valued at approximately $111,000. JPMorgan Chase & Co. lifted its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Geode Capital Management LLC lifted its position in Pharvaris by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock valued at $735,000 after purchasing an additional 1,356 shares during the period. FMR LLC raised its position in shares of Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after acquiring an additional 189,714 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Pharvaris by 11.2% in the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after acquiring an additional 994 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.